Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1975 1
1976 1
1996 1
1997 2
1998 4
1999 6
2000 6
2001 12
2002 6
2003 14
2004 23
2005 13
2006 20
2007 46
2008 81
2009 79
2010 84
2011 120
2012 143
2013 154
2014 144
2015 112
2016 126
2017 116
2018 148
2019 164
2020 231
2021 258
2022 229
2023 193
2024 162

Text availability

Article attribute

Article type

Publication date

Search Results

2,075 results

Results by year

Filters applied: . Clear all
Page 1
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P. Rouprêt M, et al. Among authors: shariat sf. Eur Urol. 2023 Jul;84(1):49-64. doi: 10.1016/j.eururo.2023.03.013. Epub 2023 Mar 24. Eur Urol. 2023. PMID: 36967359 Review.
Epidemiology and risk factors of urothelial bladder cancer.
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Burger M, et al. Among authors: shariat s. Eur Urol. 2013 Feb;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033. Epub 2012 Jul 25. Eur Urol. 2013. PMID: 22877502 Review.
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: shariat sf. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):139-148. doi: 10.1038/s41391-021-00395-4. Epub 2021 May 30. Prostate Cancer Prostatic Dis. 2022. PMID: 34054128 Free PMC article. Review.
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Tan WS, et al. Among authors: shariat sf. Eur Urol Oncol. 2022 Oct;5(5):505-516. doi: 10.1016/j.euo.2022.05.005. Epub 2022 Jun 17. Eur Urol Oncol. 2022. PMID: 35718695 Review.
Pathomics in urology.
Schuettfort VM, Pradere B, Rink M, Comperat E, Shariat SF. Schuettfort VM, et al. Among authors: shariat sf. Curr Opin Urol. 2020 Nov;30(6):823-831. doi: 10.1097/MOU.0000000000000813. Curr Opin Urol. 2020. PMID: 32881725 Review.
Urothelial carcinoma.
Merseburger AS, Shariat SF. Merseburger AS, et al. Among authors: shariat sf. World J Urol. 2011 Aug;29(4):405-7. doi: 10.1007/s00345-011-0733-9. Epub 2011 Jul 21. World J Urol. 2011. PMID: 21779833 No abstract available.
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Powles T, et al. Among authors: shariat sf. Ann Oncol. 2024 Jun;35(6):485-490. doi: 10.1016/j.annonc.2024.03.001. Epub 2024 Mar 13. Ann Oncol. 2024. PMID: 38490358 No abstract available.
Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis.
Fazekas T, Shim SR, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas JG, Gandaglia G, Szarvas T, Schoots IG, van den Bergh RCN, Leapman MS, Nyirády P, Shariat SF, Rajwa P. Fazekas T, et al. Among authors: shariat sf. JAMA Oncol. 2024 Jun 1;10(6):745-754. doi: 10.1001/jamaoncol.2024.0734. JAMA Oncol. 2024. PMID: 38576242
2,075 results